/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
At Veracyte, we believe that exceptional cancer care begins with exceptional diagnostics. We are a global diagnostics company that empowers clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer.
$44.79
+$1.36 (+3.13%)
Live · 07:28 PM
11.17% operating margin is respectable but not wide. ROIC at 4.34%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue up 16.0% YoY with margins expanding 7.6pp.
At 32x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
32.0x earnings, 22.1x FCF. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$562M
▲ +16.0% YoY
Net Income (TTM)
$114M
▲ +174.9% YoY
Op. Margin
18.82%
▲ +7.6pp YoY
ROIC
7.64%
▲ +3.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$166M
▲ +98.5% YoY
Op. Cash Flow (TTM)
$178M
▲ +81.5% YoY
Net Debt
-$259M
Net Cash Position
Cash & Equiv.
$300M
5Y CAGR: +34.5%
Continue Research
SourceComputed from the 10-Q filed 31 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 1 Aug 2026. How this is calculated.
Price from market data, live as of 2 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 32.0 and a price-to-free-cash-flow of 22.1, Veracyte (VCYT) trades below a two-stage DCF intrinsic value of about $105.27 per share, so at $44.79 the stock looks undervalued (135.0% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Veracyte scores 71/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $105.27 per share for VCYT, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $78.95. At today's $44.79, that puts the stock about 135.0% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Veracyte scores 71 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 18.8% operating margin and a 7.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. VCYT currently trades below its estimated intrinsic value and scores 71/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.